The candidate drug, TAK-875, was in the global phase-III development stage. Development was discontinued due to potential side-effects. As the drug is based on a novel mechanism of action and was positioned as a major source of future revenue, the announcement will probably affect Takeda’s stock value.
Takeda news release, December 27, 2013-12-30
Takeda stops development of Fasiglifam, a novel type-2 diabetes drug